Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.

Article  PubMed  Google Scholar 

Friedlander TW, Ryan CJ. Targeting the androgen receptor. Urol Clin North Am. 2012;39(4):453–64.

Article  PubMed  Google Scholar 

Yap TA, Zivi A, Omlin A, de Bono JS. The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol. 2011;8(10):597–610.

Article  PubMed  CAS  Google Scholar 

Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–5.

Article  PubMed  CAS  Google Scholar 

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.

Article  PubMed  CAS  Google Scholar 

Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.

Article  PubMed  CAS  Google Scholar 

Greten FR, Grivennikov SI. Inflammation and Cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Donate-Moreno MJ, Lorenzo-Sánchez MV, Díaz de Mera-Sánchez Migallón I, Herraiz-Raya L, Esper-Rueda JA, Legido-Gómez O, et al. Inflammatory markers as prognostic factors in metastatic castration-resistant prostate cancer. Actas Urol Esp (Engl Ed). 2020;44(10):692–700.

Article  PubMed  CAS  Google Scholar 

Stangl-Kremser J, Mari A, Suarez-Ibarrola R, D’Andrea D, Korn SM, Pones M, et al. Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients. Urol Oncol. 2020;38(6):600.e9-.e15

Article  Google Scholar 

Yamada Y, Sakamoto S, Rii J, Yamamoto S, Kamada S, Imamura Y, et al. Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer. Prostate. 2020;80(7):559–69.

Article  PubMed  CAS  Google Scholar 

Ocana A, Nieto-Jiménez C, Pandiella A, Templeton AJ. Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer. 2017;16(1):137.

Article  PubMed  PubMed Central  Google Scholar 

Sümbül AT, Sezer A, Abalı H, Köse F, Gültepe I, Mertsoylu H, et al. Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. Int Urol Nephrol. 2014;46(8):1531–5.

Article  PubMed  Google Scholar 

Koo KC, Lee JS, Ha JS, Han KS, Lee KS, Hah YS, et al. Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio. World J Urol. 2019;37(11):2375–84.

Article  PubMed  CAS  Google Scholar 

Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.

Article  PubMed  Google Scholar 

Linton A, Pond G, Clarke S, Vardy J, Galsky M, Sonpavde G. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clin Genitourin Cancer. 2013;11(4):423–30.

Article  PubMed  Google Scholar 

Nuhn P, Vaghasia AM, Goyal J, Zhou XC, Carducci MA, Eisenberger MA, et al. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU Int. 2014;114(6):E11–7.

PubMed  PubMed Central  CAS  Google Scholar 

Templeton AJ, Pezaro C, Omlin A, McNamara MG, Leibowitz-Amit R, Vera-Badillo FE, et al. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer. 2014;120(21):3346–52.

Article  PubMed  CAS  Google Scholar 

Yao A, Sejima T, Iwamoto H, Masago T, Morizane S, Honda M, et al. High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy. Int J Urol. 2015;22(9):827–33.

Article  PubMed  CAS  Google Scholar 

Buttigliero C, Pisano C, Tucci M, Vignani F, Bertaglia V, Iaconis D, et al. Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel. Acta Oncol. 2017;56(4):555–62.

Article  PubMed  CAS  Google Scholar 

Pei XQ, He DL, Tian G, Lv W, Jiang YM, Wu DP, et al. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China. Int Urol Nephrol. 2017;49(4):629–35.

Article  PubMed  CAS  Google Scholar 

Wu KJ, Pei XQ, Tian G, Wu DP, Fan JH, Jiang YM, et al. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China. Asian J Androl. 2018;20(2):173–7.

Article  PubMed  CAS  Google Scholar 

Bello JO, Olanipekun OO, Babata AL. Prognostic value of neutrophil-to-lymphocyte ratio in castration resistant prostate cancer: single-centre study of Nigerian men. Niger J Clin Pract. 2019;22(4):511–5.

Article  PubMed  CAS  Google Scholar 

Man YN, Chen YF. Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel. Int Urol Nephrol. 2019;51(12):2189–99.

Article  PubMed  CAS  Google Scholar 

Tatenuma T, Kawahara T, Hayashi N, Hasumi H, Makiyama K, Nakaigawa N et al. The Pretherapeutic Neutrophil-to-Lymphocyte Ratio for Docetaxel-Based Chemotherapy Is Useful for Predicting the Prognosis of Japanese Patients with Castration-Resistant Prostate Cancer. BioMed Research International. 2019;2019.

Jiang ZG, Liao SG. Baseline neutrophil-lymphocyte ratio is associated with outcomes in patients with castration-resistant prostate cancer treated with Docetaxel in South China. Med (United States). 2021;100(39).

Kobayashi H, Shiota M, Sato N, Kobayashi S, Matsumoto T, Monji K, et al. Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients. Anti-cancer Drugsp. 2022;33(1):e541–7.

Article  CAS  Google Scholar 

Neuberger M, Goly N, Skladny J, Milczynski V, Weiß C, Wessels F et al. Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort. J Cancer Res Clin Oncol. 2022.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate Cancer. Eur Urol. 2017;71(4):630–42.

Article  PubMed  Google Scholar 

Guan Y, Xiong H, Feng Y, Liao G, Tong T, Pang J. Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. Prostate Cancer Prostatic Dis. 2020;23(2):220–31.

Article  PubMed  CAS  Google Scholar 

Omlin A, Pezaro C, Gillessen Sommer S. Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol. 2014;6(1).

Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy. 2021;122(7):474–88.

PubMed  CAS  Google Scholar 

Su S, Liu L, Li C, Zhang J, Li S. Prognostic role of pretreatment derived neutrophil to lymphocyte ratio in urological cancers: a systematic review and meta-analysis. Int J Surg. 2019;72:146–53.

Article  PubMed  Google Scholar 

Yin X, Xiao Y, Li F, Qi S, Yin Z, Gao J. Prognostic role of Neutrophil-to-lymphocyte ratio in prostate Cancer: a systematic review and Meta-analysis. Med (Baltim). 2016;95(3):e2544.

Article  Google Scholar 

Tang L, Li X, Wang B, Luo G, Gu L, Chen L, et al. Prognostic Value of Neutrophil-to-lymphocyte ratio in localized and advanced prostate Cancer: a systematic review and Meta-analysis. PLoS ONE. 2016;11(4):e0153981.

Article